tbuckley/cabot-search huggingface dataset:
Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer
Authors: Giuseppe Pelosi, Patrizia Gasparini, Davide Conte, Alessandra Fabbri, Federica Perrone, Elena Tamborini, Serenella M. Pupa, Valentina Ciravolo, Roberto Caserini, Giulio Rossi, Alberto Cavazza, Mauro Papotti, Yukio Nakatani, Patrick Maisonneuve, Ugo Pastorino, Gabriella Sozzi
Journal: Journal of Thoracic Oncology (2016)
START: Susceptibility to Food Allergies in a Registry of Twins
Authors: Sarah De Schryver, Alizee Dery, Ann Elaine Clarke, Kari C. Nadeau, Laurie Harada, Celia Greenwood, Kimberley Weatherall, Denise Daley, Yuka Asai, Fiona Bamforth, Moshe Ben-Shoshan
Journal: Journal of Allergy and Clinical Immunology (2016)
Induction of Intestinal and Urinary Bladder Cancer in Rats by Feeding Bracken Fern &lt;italic&gt;(Pteris aquilina)&lt;/italic&gt;&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: A M Pamukcu, J M Price
Journal: JNCI Journal of the National Cancer Institute (1969)

Simultaneous intestinal and urinary bladder tumors were induced in rats by feeding them bracken fern (Pteris aquilina). Adenomatous polyps and adenocarcinomas developed predominantly in the ileum. These neoplasms were homogeneous and were sharply demarcated from adjacent normal mucosa. Urinary bladder tumors consisted of papillomas and carcinomas, and a high degree of malignancy followed the bracken feeding.
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF, sargramostim) administration on serum S100B and its subtypes in melanoma patients
Authors: B. De Gast, C. Korse, R. Weber, S. Trautveter, J. Bonfrer, L. Spitler
Journal: Journal of Clinical Oncology (2007)

8563 Background: Serum S100B is a tumor marker for malignant melanoma (MM) and is also a histological marker for Dendritic Cells (DC). Previously study we found that DC only expressed the S100BB subtype, whereas MM expressed both the S100A1B and BB subtypes. As GM-CSF can induce activation of DC, we studied if such therapy also increased serum S100B and analysed the subtype of the increased S100B. Methods: Forty-three patients with MM were treated after surgical cytoreduction with adjuvant GM-CSF, 125 μg/m 2 subcutaneously for up to 1 year in 28-day cycles of 14 days on followed by 14 days rest. Serum S100B was measured before therapy (d0), following 14 days on GM-CSF (d15), and after 14 days off GM-CSF (d29), as well as d155. If serum S100B was increased, subtype analysis was performed with immunoassays for S100A1B and S100BB. Results: In 39 patients with a normal serum S100B at d0 (mean 0.04 ± sd 0.02 μg/l), a significant rise of serum S100B occurred at d15 (mean 0.09 ± sd 0.04 μg/l), returning to normal at d29 (mean 0.05 ± sd 0.02, p&lt;0.001 for d15 versus d0 and d29). Analysis of the increased S100B at d15 showed increased levels of S100BB in 7/13 patients and no increase in the levels of S100A1B. In 4 patients S100B was increased at d0, of the S100A1B subtype in 2 with rapidly progressive disease. The other 2 had only increased S100BB levels. In 28 patients a significant increase occurred at d155. Overall, 18 patients have remained without evidence of disease all without S100A1B. Four patients developed metastatic disease and had increased levels of S100A1B; however 6 additional patients also developed metastasis without an increase in S100A1B. Conclusions: Administration of GM- CSF causes an increase of S100BB suggestive of activation of DC. Increased levels of S100A1B were indicative of active MM, but the absence of elevated S100A1B did not exclude metastasis. No significant financial relationships to disclose.
Investigation on release of MTX combined with calcium sulfate in vitro
Authors: yang dong
Journal: Clinical Cancer Research (2007)

AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

B39 

Abstract     The purpose of the study was to investigate the character of drug release of calcium sulfate (OSTEOSET®) combined with MTX in the circumstance of Tris-buffered natural saline. The drug particles combined with 20 mg MTX, 4% in weight percentage, were made manually. The experiment was carried under the condition of 37°C in temperature, rotation rate 50rpn. The mimesis of body fluid was Tris-buffered natural saline. The extraction method was adopted. Samples were collected every 2 hours in the first 24hours and everyday in the next 20 days. The drug concentration of each sample was analyzed through high performance liquid chromatogram. Twenty-five particles were put into the experiment, and twenty were observed throughout the experiment. The average drug concentration of the first two hours was 10.535mg/L, the highest of the first twenty-four hours, and maintains between 4 mg/L and 6mg/L latterly. There was an exponential relation between the accumulative drug concentration and the square root of sampling time. As a carrier, OSTEOSET® combined with 4% MTX, totally drug amount to 20 mg per drug particle, the drug release was faster in the first 3 days, remained in a steady state for 15 days. The drug concentration maintains 65mg/L and 100mg/L in the steady period. It was a quite ideal local drug release carrier.    Key Words: Calcium sulfate, Drug implants, MTX, HPLC
Abstract 12225: Renovascular Interaction in Children With Congenital Heart Disease
Authors: Hirofumi Saiki, Hirotaka Ishido, Satoshi Masutani, Masanori Tamura, Hideaki Senzaki
Journal: Circulation (2013)

Background: Increased arterial stiffness can cause renal dysfunction via microvascular damage, consequently contributing to impaired arterial function by several mechanisms including elevation of b...
Heparin suppresses endothelin-1 peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats.
Authors: K Yokokawa, M Kohno, A K Mandal, H Tahara, M Yanagisawa, T Takeda, M ] Kohne M [corrected to Kohno
Journal: Journal of the American Society of Nephrology (1994)

Heparin given sc consistently lowers blood pressure in spontaneously hypertensive rats (SHR). This study was designed to examine heparin's effect on vasoconstrictor endothelin-1 production in cultured aortic endothelial cells (EC). Aortic EC from SHR and normotensive Wistar Kyoto rats (WKY) were cultured and incubated with or without different concentrations of heparin. Heparin suppressed endothelin-1 release and endothelin-1 mRNA expression in a dose- and a time-dependent fashion in both WKY and SHR. The suppressive effects were more augmented in SHR than in WKY: SHR versus WKY--endothelin-1 level at 6 h = 8 +/- 1.8 versus 14 +/- 2.2 pg/10(6) cells (P < 0.01) and mRNA expression--85 versus 52% maximal inhibition by heparin, 10 U/mL (=70 micrograms/mL) (P < 0.01). When heparin was added with transcriptional inhibitor actinomycin D and incubated for 30 min, no further inhibition of endothelin-1 mRNA level measured after another 30 minutes was observed compared with the endothelin-1 mRNA level in cultured EC of SHR treated with just actinomycin D at 30 min. These results suggest that heparin regulates endogenous endothelin-1 production by cultured EC, probably at the transcriptional level, and that this effect is more marked in SHR than in WKY.
Health-related quality of life (HRQL) and patient-reported outcomes (PRO) in COPD patients receiving add-on-therapy with EPs® 7630
Authors: Heinrich Matthys, Dina Pliskevich, Thorsten Reineke, Fathi-Abdul Malek
Journal: European Respiratory Journal (2011)

HRQL and PRO are important measures for treatment evaluation and assessment of health condition.  In an RCT (ISRCTN01681733) in patients with COPD stage II/III, add-on therapy with EPs® 7630, a herbal drug preparation from Pelargonium sidoides roots (Umckaloabo®; ISO Arzneimittel, Ettlingen, GER), significantly prolonged time to exacerbations and reduced their frequency. We also investigated HRQL and further PRO parameters assessed during the trial.  Patients with a standardised COPD baseline treatment according to GOLD were randomly allocated to a double-blind 24-week oral add-on therapy with 30 drops EPs® 7630 (n=99) or placebo (n=101) thrice daily. HRQL/PRO were assessed by St. George9s Respiratory Questionnaire (SGRQ), EQ-5D, Integrative Medicine Patient Satisfaction Scale (IMPSS), Integrative Medicine Outcomes Scale (IMOS), patient-reported intensity score of cough, sputum production and sternal pain while coughing, and drug tolerability.  After 24 weeks, patients treated with EPs® 7630 reported a significantly more improved HRQL compared to placebo (SGRQ total score, p   Conclusion:  Add-on-therapy with EPs® 7630 led to a statistically significant and clinically relevant improvement of HRQL and other PRO (total score difference of SGRQ >4 points) including good long-term tolerability in patients with COPD stage II and III.
Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors.
Authors: A L Cheng, I J Su, Y C Chen, T C Lee, C H Wang
Journal: Journal of Clinical Oncology (1993)

PURPOSE We previously have reported the poor prognoses of recurrent peripheral T-cell lymphoma (PTCL) and Epstein-Barr virus (EBV)-associated PTCL (J Clin Oncol 7:725-731, 1989; Blood 77:799-808, 1991). To study the role that drug resistance plays in this scenario, we conducted a retrospective study of 23 adult patients. PATIENTS AND METHODS All patients had recurrent lymphoma tissue available for immunophenotyping and screening for the existence of EBV DNA in tumor cells by Southern blot analysis and in situ hybridization. Expression of a multidrug resistance P-glycoprotein ([P-gp]mdr-1) and a glutathione redox cycle-related glutathione-S-transferase pi (GST-pi) was determined by an immunohistochemistry method. RESULTS Expression of mdr-1 or GST-pi was found in 11 (48%) and 12 (52%) cases, respectively. Most (11 of 12) of the GST-pi expression occurred simultaneously with mdr-1. Prechemotherapy tumor tissues were available in 11 cases; only two (18.2%) of these cases expressed mdr-1. Four (36%) of 11 cases that expressed mdr-1 (mdr-1(+)) and nine (90%) of 10 cases that did not express mdr-1 (mdr-1(-)) responded to second-line chemotherapy (P &lt; .05). The survival-after-recurrence (SAR) curves significantly favored mdr-1(-) recurrent lymphoma (P &lt; .05). The mdr-1 expression was further correlated with the immunophenotype and EBV association. All six cases of EBV-associated lymphoma (PTCL, five cases; Hodgkin's disease, one case) had significant simultaneous expression of mdr-1 and GST-pi in their recurrent tumor tissues. CONCLUSION (1) mdr-1 expression is a significant prognostic factor in recurrent lymphomas; (2) high expression of mdr-1 is observed in recurrent EBV-associated PTCL; and (3) GST-pi usually expresses simultaneously with mdr-1 in recurrent lymphomas. The role of EBV in the development of mdr-1 and the biologic significance of the simultaneous expression of mdr-1 and GST-pi in recurrent lymphomas are well worth further exploration.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Authors: Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally, Scott A Tomlins, David M Nanus, Scott T Tagawa, Eliezer M Van Allen, Olivier Elemento, Andrea Sboner, Levi A Garraway, Mark A Rubin, Francesca Demichelis
Journal: Nature Medicine (2016)
Coexistence of Two Functioning T-Cell Repertoires in Healthy Ex-Thalassemics Bearing a Persistent Mixed Chimerism Years After Bone Marrow Transplantation
Authors: Manuela Battaglia, Marco Andreani, Marisa Manna, Sonia Nesci, Paola Tonucci, Barbara Persini, Gioacchino Robustelli della Cuna, Arcangelo Nocera, Jack Gorski, Guido Lucarelli, Raffaele De Palma
Journal: Blood (1999)
Natural history and management of pneumothoraces in a tertiary centre
Authors: Anoop Prakash, Sega Pathmanathan, Shoaib Faruqi, Anthony Arnold, Jaymin Morjaria, Jack Kastelik
Journal: European Respiratory Journal (2014)

Background : Pneumothoraces are a relatively common condition and are broadly classified as spontaneous and traumatic or iatrogenic. Spontaneous pneumothoraces can be subdivided into primary (PSP) and secondary spontaneous pneumothorax (SSP).

Aim : To ascertain the type, natural history and management of pneumothorax cases in our tertiary centre.

Methods : We retrospectively analysed data from patients managed by our pleural service between April 2012 and January 2014. We evaluated the maximum size of the pneumothorax (in cm) on chest radiography as well as the time to resolution (in days) in these individuals. In addition, we assessed the various methods adopted in the management of these patients.

Results : We identified 100 cases of pneumothorax; 53 of these were right sided, 46 were left sided and 1 was bilateral. Our findings are summarised in the table.

View this table:

table1 Natural history & management by pneumothorax type





Conclusions : In accordance with recommendations, a large proportion of the SSPs (83%) were appropriately managed with intervention. However, only 27.6% of individuals with a PSP were observed. In our local population of such high smoking prevalence, it may be the case that the higher number of interventions in PSPs could be due to underlying undiagnosed disease.
Acquired <scp><i>TERT</i></scp> promoter mutations stimulate <scp><i>TERT</i></scp> transcription in mantle cell lymphoma
Authors: Julieta Panero, Raquel M. Alves‐Paiva, Alejandro Roisman, Barbara A. Santana‐Lemos, Roberto P. Falcão, Gustavo Oliveira, Diego Martins, Carmen Stanganelli, Irma Slavutsky, Rodrigo T. Calado
Journal: American Journal of Hematology (2016)

Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm with poor prognosis. Acquired telomerase reverse transcriptase gene promoter (TERTp) mutations are among the most frequent somatic non-coding mutations in cancers. In this study, the prevalence of TERTp mutations in 24 MCL and 21 other lymphoid neoplasias (oLN) was investigated. Eight MCL samples (33%) carried TERTp mutations, two homozygous and six heterozygous (seven C228T and one C250T), which directly correlated with higher TERT transcription, mitochondrial DNA copy number, and IGHV mutational status in MCL neoplastic cells. TERTp mutations were not found in oLN. TERTp mutations correlated with more lymphoma proliferation and tumor burden, as suggested by the higher number of lymphoma cells circulating in peripheral blood, and tended to associate with longer MCL telomeres, especially in homozygous mutants, although not statistically significant. Telomere-biology genes were overexpressed in MCL cells in comparison to healthy lymphocytes, but were not influenced by mutation status. The findings described for the first time that acquired TERTp mutations are common in MCL but not in other lymphoid neoplasms. It was also demonstrated that TERTp mutations are associated with higher TERT mRNA expression in MCL cells in vivo and higher tumor burden, suggesting these mutations as a driver event in MCL development and progression.
Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)
Authors: E. B. Garon, S. Sadeghi, F. F. Kabbinavar, K. L. Reckamp, D. C. Marquez-Garban, L. P. Stabile, L. Goodglick, S. M. Dubinett, J. M. Siegfried, R. J. Pietras
Journal: Journal of Clinical Oncology (2008)

19091 Background: Laboratory work shows that NSCLC cells and primary tumors express estrogen receptors (ER) that contribute to growth promotion (Stabile et al. Cancer Res. 62: 2141, 2002; Weinberg et al. Cancer Res. 65: 11287, 2005). Preclinical evaluation demonstrates considerable interaction between the ER and EGFR pathways with additive effects on NSCLC cell lines when both pathways are inhibited. We designed a phase II study to evaluate whether inhibition of ER with the ER downregulator, fulvestrant (F), could add to the anti-tumor efficacy of EGFR inhibition with erlotinib (E). The study design includes an interim safety analysis after 5 patients receive E+F, as no safety data with this combination was available at study onset. Methods: Men and women (pre- and post-menopausal) with advanced NSCLC and at least one prior chemotherapy regimen are randomly assigned in a 2:1 ratio to receive E (150 mg PO qd) with or without high-dose F (500 mg IM q2wk x 3, then q4wk). The primary endpoint is response rate at 2 months. Secondary endpoints include correlation between response and ERα, ERβ, EGF/HER-1 receptor and HER-2/neu expression. Results: 14 patients have been enrolled, 9 assigned to E+F (one withdrew prior to therapy) and 5 to E. On the E+F arm, 1 patient withdrew at d18 for a grade 3 rash. On the E arm, 1 patient had visible progression of a chest wall mass at d28. All remaining patients completed at least 8 weeks of therapy. One patient receiving E+F developed a GI bleed complicated by MI at d95. No other grade 3 or 4 toxicities were seen. The most common toxicity was rash, with little difference in overall toxicity between the two arms. Conclusions: In this group of previously treated men and women with NSCLC, the tolerability of E+F is acceptable. Therefore, the Data Safety and Monitoring Board allowed the study to continue. Per protocol, we can now expand the study beyond UCLA, and we plan to involve the TORI research network to help complete accrual and evaluate for efficacy of the combination in men and women with advanced NSCLC. [Supported by NIH Lung Cancer SPORE P50-CA90388 and P50-CA90440, AstraZeneca, Genentech, Stiles Program] Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca Oncology, Genentech™ BioOncology
A Transplantable Lymphoma Induced With Marek's Disease Virus 2 3
Authors: R. M. Jakowski, T. N. Fredrickson, L. W. Schierman, R. A. McBride
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article A Transplantable Lymphoma Induced With Marek's Disease Virus Get access R. M. Jakowski, R. M. Jakowski 4Department of Pathobiology, U-89, University of Connecticut, Storrs, Conn. 06268. Search for other works by this author on: Oxford Academic PubMed Google Scholar T. N. Fredrickson, T. N. Fredrickson 4Department of Pathobiology, U-89, University of Connecticut, Storrs, Conn. 06268. Search for other works by this author on: Oxford Academic PubMed Google Scholar L. W. Schierman, L. W. Schierman 5Department of Pathology, New York Medical College, Valhalla, N.Y. 10595. Search for other works by this author on: Oxford Academic PubMed Google Scholar R. A. McBride R. A. McBride 5Department of Pathology, New York Medical College, Valhalla, N.Y. 10595. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 3, September 1974, Pages 783–789, https://doi.org/10.1093/jnci/53.3.783 Published: 01 September 1974 Article history Received: 07 February 1974 Accepted: 10 May 1974 Published: 01 September 1974
Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.
Authors: R P Abratt, W R Bezwoda, L Goedhals, D J Hacking
Journal: Journal of Clinical Oncology (1997)

PURPOSE The aim of this study was to examine the efficacy of a regimen of initial gemcitabine followed by cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Fifty-three patients (36 men and 17 women; age range, 35 to 74 years) were enrolled. Patients had bidimensionally measurable disease. Gemcitabine (phase-specific agent) was administered on days 1, 8, and 15 at a dose of 1,000 mg/m2. Cisplatin (cycle-specific agent) was administered on day 15 (100 mg/m2). Chemotherapy was administered in 28-day cycles. RESULTS Of 53 patients enrolled, 50 were assessable for response. The overall response rate was 52%. There were two complete responses (4%) and 24 partial responses (48%). The median survival duration was 13 months and the 1-year survival rate was 61%. The regimen was generally well tolerated. World Health Organization (WHO) grade 3 and 4 neutropenia occurred in 38.8% and 19.2% of patients, respectively. Grade 3 and 4 thrombocytopenia occurred in 13.3% and 7.7% of patients, respectively. Most patients experienced mild nausea and vomiting. Few patients had hair loss and oral toxicity was mild. Relatively few patients required dose modifications for any of the three weekly doses of chemotherapy. For the first two cycles of chemotherapy, the dose-intensity per infusion was 947 mg/m2 for gemcitabine and 85 mg/m2 for cisplatin. CONCLUSION This regimen of gemcitabine and cisplatin was effective, with high response and survival rates and few dosage modifications during its administration. Prospective randomized studies with other cisplatin-based combination chemotherapy regimens are indicated.
Metrics in Urban Health: Current Developments and Future Prospects
Authors: Amit Prasad, Chelsea Bettina Gray, Alex Ross, Megumi Kano
Journal: Annual Review of Public Health (2015)

The research community has shown increasing interest in developing and using metrics to determine the relationships between urban living and health. In particular, we have seen a recent exponential increase in efforts aiming to investigate and apply metrics for urban health, especially the health impacts of the social and built environments as well as air pollution. A greater recognition of the need to investigate the impacts and trends of health inequities is also evident through more recent literature. Data availability and accuracy have improved through new affordable technologies for mapping, geographic information systems (GIS), and remote sensing. However, less research has been conducted in low- and middle-income countries where quality data are not always available, and capacity for analyzing available data may be limited. For this increased interest in research and development of metrics to be meaningful, the best available evidence must be accessible to decision makers to improve health impacts through urban policies.